Disclosure of Share Capital and Voting Rights Outstanding as of July 31, 2018

(Pursuant to Article L.233-8 II of the French Commercial Code and articles 221-1 and 223-16 of the General Regulations of the Autorité des Marchés Financiers )

Charenton-le-Pont, France (August 6, 2018 - 6.00 p.m.) - As of July 31, 2018, shares and voting rights outstanding of Essilor, the world leader in ophthalmic optics, broke down as follows:

  July 31, 2018
Shares outstanding 219,146,521
Exercisable voting rights 234,253,244
Total voting rights, based on all outstanding shares, including shares stripped of their voting rights* 235,590,074

(*) Shares held by the Company.

About Essilor Essilor International (Compagnie Générale d'Optique) ("Essilor") is the world's leading ophthalmic optics company. Essilor designs, manufactures and markets a wide range of lenses to improve and protect eyesight. Its mission is to improve lives by improving sight. To support this mission, Essilor allocates more than €200 million to research and innovation every year, in a commitment to continuously bring new, more effective products to market. Its flagship brands are Varilux ® , Crizal ® , Transitions ® , Eyezen TM , Xperio ® , Foster Grant ® , Bolon TM and Costa ® . It also develops and markets equipment, instruments and services for eyecare professionals. Essilor reported consolidated revenue of around €7.5 billion in 2017 and employs approximately 67,000 people worldwide. It has 34 plants, 481 prescription laboratories and edging facilities, as well as 4 research and development centers around the world. For more information, please visit www.essilor.com . The Essilor share trades on the Euronext Paris market and is included in the Euro Stoxx 50 and CAC 40 indices.  Codes and symbols: ISIN: FR0000121667; Reuters: ESSI.PA; Bloomberg: EI:FP.

------------------------

Investor Relations and Financial Communications Phone: +33 (0)1 49 77 42 16

Attachment